Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261498 | 1.00 | RNPEP (0.41) | RNPEPSLC7A5ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL263453 | 0.84 | HTT (0.35) | RNPEPSLC7A5ALDH1A1CPA1MEN1 | |
| SCHEMBL262272 | 0.84 | HTT (0.35) | RNPEPSLC7A5ALDH1A1CPA1MEN1 | |
| SCHEMBL3467830 | 0.84 | HTT (0.35) | RNPEPSLC7A5ALDH1A1CPA1MEN1 | |
| SCHEMBL261441 | 0.84 | HTT (0.35) | RNPEPSLC7A5ALDH1A1CPA1MEN1 | |
| SCHEMBL260952 | 0.84 | HTT (0.35) | RNPEPSLC7A5ALDH1A1CPA1MEN1 | |
| SCHEMBL8276004 | 0.83 | RNPEP (0.41) | RNPEPSLC7A5ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL15688388 | 0.83 | RNPEP (0.41) | RNPEPSLC7A5ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL2920755 | 0.82 | HTT (0.34) | RNPEPSLC7A5ALDH1A1CPA1MEN1 | |
| SCHEMBL262101 | 0.82 | HTT (0.34) | RNPEPSLC7A5ALDH1A1CPA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831154-B1 | PREPARATION OF PREGABALIN AND RELATED COMPOUNDS | WARNER LAMBERT CO (US) | 2010-01-13 | — | — | EP | claimed |
| US-20090042262-A1 | Preparation of Pregabalin and Related Compounds | PFIZER INC | 2009-02-12 | — | — | US | claimed |
| US-20050283023-A1 | Preparation of pregabalin and related compounds | HU SHANGHUI | 2005-12-22 | — | — | US | claimed |
| US-6891059-B2 | Asymmetric synthesis of pregabalin | WARNER-LAMBERT COMPANY (US) | 2005-05-10 | — | — | US | claimed |
| EP-1250311-B1 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | claimed |
| US-20030212290-A1 | Asymmetric synthesis of pregabalin | BURK MARK JOSEPH (US) | 2003-11-13 | — | — | US | claimed |
| EP-1250311-A1 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER-LAMBERT COMPANY (US) | 2002-10-23 | — | — | EP | claimed |
| WO-2001055090-A1 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| WO-2023088077-A1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF PREGABALIN INTERMEDIATES | ENZYMASTER (NINGBO) BIO-ENGINEERING CO., LTD. (CN) | 2023-05-25 | — | — | WO | disclosed |
| US-8134023-B2 | Preparation of pregabalin and related compounds | PFIZER INC (US) | 2012-03-13 | — | — | US | disclosed |
| US-20120015412-A1 | Preparation of Pregabalin and Related Compounds | PFIZER INC | 2012-01-19 | — | — | US | disclosed |
| US-8044227-B2 | Preparation of pregabalin and related compounds | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110065168-A1 | Preparation of Pregabalin and Related Compounds | PFIZER INC | 2011-03-17 | — | — | US | disclosed |
| US-7838686-B2 | Preparation of pregabalin and related compounds | PFIZER INC. (US) | 2010-11-23 | — | — | US | disclosed |
| WO-2010070593-A2 | MALONATE ESTERS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2010-06-24 | — | — | WO | disclosed |
| EP-1831154-B1 | PREPARATION OF PREGABALIN AND RELATED COMPOUNDS | WARNER LAMBERT CO (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-1831154-B1 | PREPARATION OF PREGABALIN AND RELATED COMPOUNDS | WARNER LAMBERT CO (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090042262-A1 | Preparation of Pregabalin and Related Compounds | PFIZER INC | 2009-02-12 | — | — | US | disclosed |
| WO-2006000904-A2 | PREPARATION OF PREGABALIN AND RELATED COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050283023-A1 | Preparation of pregabalin and related compounds | HU SHANGHUI | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212290-A1 | Asymmetric synthesis of pregabalin | GABRA5, GABRA6, GABRE | RNPEP 3548/4885SLC7A5 656/4885ALDH1A1 626/4885 |
| US-20090042262-A1 | Preparation of Pregabalin and Related Compounds | GABRE, GABRG1, GABRA6 | RNPEP 444/4885SLC7A5 1853/4885ALDH1A1 786/4885 |
| US-20050283023-A1 | Preparation of pregabalin and related compounds | GABRE, GABRG1, GABRA6 | RNPEP 444/4885SLC7A5 1853/4885ALDH1A1 786/4885 |
| US-20110065168-A1 | Preparation of Pregabalin and Related Compounds | GABRE, GABRG1, GABRA6 | RNPEP 444/4885SLC7A5 1853/4885ALDH1A1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.